Astrana Health (NASDAQ:ASTH) Earns Buy Rating from Analysts at TD Cowen

TD Cowen initiated coverage on shares of Astrana Health (NASDAQ:ASTH) in a research note published on Monday morning, MarketBeat Ratings reports. The firm issued a buy rating and a $66.00 target price on the stock.

ASTH has been the subject of several other reports. Robert W. Baird raised their target price on shares of Astrana Health from $54.00 to $67.00 and gave the stock an “outperform” rating in a research report on Thursday, August 15th. BTIG Research lifted their price objective on Astrana Health from $60.00 to $70.00 and gave the company a “buy” rating in a research report on Thursday, October 3rd. Truist Financial increased their target price on Astrana Health from $50.00 to $59.00 and gave the stock a “buy” rating in a research report on Friday, August 9th. Stifel Nicolaus lifted their price target on Astrana Health from $48.00 to $60.00 and gave the company a “buy” rating in a research report on Thursday, August 1st. Finally, KeyCorp began coverage on Astrana Health in a report on Friday, October 11th. They issued a “sector weight” rating for the company. One investment analyst has rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, Astrana Health currently has an average rating of “Buy” and a consensus target price of $62.00.

Astrana Health Stock Up 2.4 %

NASDAQ ASTH opened at $62.54 on Monday. Astrana Health has a 1 year low of $28.86 and a 1 year high of $63.20. The stock has a market capitalization of $3.50 billion, a PE ratio of 47.38, a PEG ratio of 2.20 and a beta of 1.21. The company has a debt-to-equity ratio of 0.62, a current ratio of 1.84 and a quick ratio of 1.84. The business’s 50-day moving average is $52.28 and its 200 day moving average is $45.48.

Astrana Health (NASDAQ:ASTH) last issued its quarterly earnings data on Wednesday, August 7th. The company reported $0.40 earnings per share for the quarter, topping analysts’ consensus estimates of $0.39 by $0.01. The firm had revenue of $486.30 million for the quarter, compared to analyst estimates of $440.68 million. Astrana Health had a return on equity of 10.71% and a net margin of 4.30%. The business’s quarterly revenue was up 39.7% compared to the same quarter last year. During the same period last year, the company earned $0.28 EPS. Sell-side analysts forecast that Astrana Health will post 1.33 earnings per share for the current year.

Institutional Investors Weigh In On Astrana Health

Institutional investors have recently modified their holdings of the stock. GAMMA Investing LLC bought a new position in Astrana Health in the 3rd quarter worth about $34,000. Central Pacific Bank Trust Division purchased a new position in Astrana Health in the third quarter worth about $160,000. Granite Bay Wealth Management LLC bought a new position in shares of Astrana Health in the third quarter worth approximately $290,000. Handelsbanken Fonder AB bought a new position in shares of Astrana Health in the third quarter worth approximately $492,000. Finally, SG Americas Securities LLC bought a new stake in shares of Astrana Health during the third quarter valued at approximately $680,000. 52.77% of the stock is owned by hedge funds and other institutional investors.

Astrana Health Company Profile

Astrana Health, Inc, Inc, a physician-centric technology-powered healthcare management company, provides medical care services in the United States. It operates through three segments: Care Partners, Care Delivery, and Care Enablement. The company is leveraging its proprietary population health management and healthcare delivery platform, operates an integrated, value-based healthcare model which empowers the providers in its network to deliver care to its patients.